| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, See Remarks And Footnotes | 10% Owner | Director, See Explanation Of Responses +5 more
17 companies
Bvf Partners L P/il is a See Explanaton Of Responses at CYTK with holdings across 17 companies. Recent SEC Form 4 filings include 37 buys and 0 sells.
Estimated insider holdings value: $664.8M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 27, 2022 | KYMR Kymera Therapeutics, Inc. | Director, See Remarks And Footnotes | Buy | 289,426 | $14.34 | $4,150,321.26 | +3.7% | +114.8% | +95.5% | |
| May 20, 2022 | KYMR Kymera Therapeutics, Inc. | Director, See Remarks And Footnotes | Buy | 10,100 | $14.00 | $141,393.94 | +0.3% | +96.7% | +100.5% | |
| May 18, 2022 | RPTX Repare Therapeutics Inc. | 10% Owner | Buy | 420,000 | $8.50 | $3,570,000.00 | +7.3% | +33.1% | +4.2% | |
| May 13, 2022 | CGEM Cullinan Therapeutics, Inc. | 10% Owner | Buy | 1,109,900 | $9.07 | $10,063,936.50 | +9.4% | +25.0% | -8.1% | |
| May 6, 2022 | KYMR Kymera Therapeutics, Inc. | Director, See Remarks And Footnotes | Buy | 250,000 | $19.46 | $4,865,365.00 | +3.5% | +47.7% | +52.4% | |
| Apr 1, 2022 | CGEM Cullinan Therapeutics, Inc. | 10% Owner | Buy | 276,000 | $10.75 | $2,966,972.40 | +5.5% | +16.7% | -6.9% | |
| Jan 31, 2022 | KYMR Kymera Therapeutics, Inc. | Director, See Remarks | Buy | 130,309 | $38.96 | $5,076,473.14 | +2.0% | -22.1% | -11.0% | |
| Jan 24, 2022 | KYMR Kymera Therapeutics, Inc. | Director, See Remarks | Buy | 272,767 | $37.76 | $10,300,636.60 | +9.4% | -13.5% | -6.5% | |
| Jan 19, 2022 | RPTX Repare Therapeutics Inc. | 10% Owner | Buy | 997,961 | $14.10 | $14,071,250.10 | +21.0% | -17.0% | -14.7% | |
| Nov 30, 2021 | OLMA Olema Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 739,675 | $9.39 | $6,945,770.15 | +11.6% | -46.5% | -67.2% |